Special Issue "Recent Advances in Cellular Immunotherapy"
A special issue of Medical Sciences (ISSN 2076-3271).
Deadline for manuscript submissions: closed (30 November 2013)
Dr. Subramaniam Malarkannan
Laboratory of Molecular Immunology and Immunotherapy, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
Phone: +1 414 937 3812
Fax: +1 414 937 6284
Interests: NK cell development and functions; Biochemical and genetic analyses of signaling cascades in NK cells; NK cell-mediated epithelial cell regeneration during influenza infections; NK cell-based cellular immunotherapy for patients with hematological malignancies
In the past decade, academic perseverance and industrial fortitudes revolutionized the positive outcome of cancer therapy and thereby tremendously improving the rate of patient survival. Although it has been kept in the back-burner by the success of novel concoctions of pharmacological compounds, in the past two years cellular immunotherapy has made a roaring comeback. Clinicians and basic scientist alike think and desire of combinatorial and individualized therapies where treatment regimens can be customized to fit with the type and stage of tumor growth. More importantly, the promise of cellular immunotherapy can keep the viciousness of the treatment-related side effects in check. Genetically manipulated lymphocytes including T and NK cells are better than ever in clearing and killing tumor cells. Lymphocytes that are made to express antibody-based Chimeric Antigen Receptor (CAR) function with a significantly higher affinity compared to using their native receptors. Addition of critical cytokines and their receptors in the mix has realigned the basic immunological rules, resulting in a stronger lymphocyte response against malignancies. Although we can feel the excitement about the recent success in cellular immunotherapy methods on the lab benches and hospital beds, they are yet to reach their prime and still have their perils. Cytokine-release syndrome is a major unwanted side effect that we counter when we genetically amplify the immune response. In the first issue of Medical Sciences, we would like to provide a detailed account of the recent advances made in cellular immunotherapy. The good, the worthy and the bad of cellular immunotherapy in one issue!
Dr. Subramaniam Malarkannan
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- cellular immunotherapy
- genetically modified T and NK cells
- chimeric antigen receptors
- genetic manipulation and generation of novel
- high affinity antigen receptors
- tumor antigens
- cytokines and cytokine receptors
- co-stimulatory receptors
- altering signaling cascades in lymphocytes
- cytokine-release syndrome
Med. Sci. 2014, 2(2), 82-97; doi:10.3390/medsci2020082
Received: 4 October 2013; in revised form: 8 March 2014 / Accepted: 25 March 2014 / Published: 14 April 2014| PDF Full-text (685 KB) | HTML Full-text | XML Full-text
Article: In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples
Med. Sci. 2014, 2(2), 70-81; doi:10.3390/medsci2020070
Received: 14 November 2013; in revised form: 3 March 2014 / Accepted: 4 March 2014 / Published: 26 March 2014| Cited by 1 | PDF Full-text (498 KB) | HTML Full-text | XML Full-text
Article: Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines
Med. Sci. 2014, 2(1), 51-69; doi:10.3390/medsci2010051
Received: 2 December 2013; in revised form: 27 January 2014 / Accepted: 27 January 2014 / Published: 20 February 2014| PDF Full-text (3225 KB) | HTML Full-text | XML Full-text
Med. Sci. 2014, 2(1), 23-36; doi:10.3390/medsci2010023
Received: 3 December 2013; in revised form: 22 January 2014 / Accepted: 22 January 2014 / Published: 28 January 2014| PDF Full-text (358 KB) | HTML Full-text | XML Full-text
Med. Sci. 2014, 2(1), 1-22; doi:10.3390/medsci2010001
Received: 15 November 2013; in revised form: 16 December 2013 / Accepted: 16 December 2013 / Published: 27 December 2013| PDF Full-text (684 KB) | HTML Full-text | XML Full-text
Review: Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells
Med. Sci. 2013, 1(1), 37-48; doi:10.3390/medsci1010037
Received: 29 September 2013; in revised form: 21 October 2013 / Accepted: 11 November 2013 / Published: 15 November 2013| PDF Full-text (989 KB) | HTML Full-text | XML Full-text
Last update: 12 November 2013